Hernández-Mitre MP, Morpeth S, Venkatesh B, Hills TE, Davis J, Mahar RK, McPhee G, Jones M, Totterdell J, Tong SYC, Roberts JA. TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of randomized clinical trials of nafamostat and camostat mesylate. Clin Microbiol Infec. 2024;30:743–54.

Article  Google Scholar 

Jang S, Rhee L-Y. Three cases of treatment with nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy. Int J Infect Dis. 2020;96:500–2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin Y, Shao Y, Liu Y, Yang R, Liao S, Yang S, Xu M, He J. Efficacy and safety of nafamostat mesylate anticoagulation I blood purification treatment of critically ill patients: a systematic review and meta-analysis. Ren Fail. 2022;44:1264–80.

Article  Google Scholar 

Qian W, He C, Ren Y, Xian X, Jiang Z, Xu S. Application of nafamostat mesylate for anticoagulation in hemoperfusion therapy in patients with bromadiolone poisoning: case reports. Heliyon. 2023;9: e19811.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nakae H, Tajimi K. Pharmacokinetics of nafamostat mesylate during continuous hemodiafiltoration with a polyacrylonitrile membrane. Therap Apher Dialysis. 2003;7:483–5.

Article  CAS  Google Scholar 

Yamasaki K, Nishi K, Tsukigawa K, Taguchi K, Otagiri M, Seo H. Possible role of electrolytes on the formation of precipitates during the infusion of nafamostat mesylate in hemodialysis. Biol Pharm Bull. 2021;44:259–65.

Article  CAS  PubMed  Google Scholar 

Sano K, Iwamoto H, Tokkitoh Y, Koga N. Tousekieki to Nafamostat mesylate salt seizai no konngou de shoujirtaseishutsu no kenshou. Nihonrinshoukougakugishikaisi. 2017;59:102–5 (in Japanese).

Google Scholar 

Hitomi Y, Ikari N, Fujii S. Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system. Pathophysiol, Haemostasis Throm. 1985;3:164–8.

Article  Google Scholar 

Aoyama T, Ino Y, Ozeki M, Oda M, Sato T, Koshiyama Y, Suzuki S, Fujita M. Pharmacological stuies of FUT-175, nafamostat mesylate I. Inhibition of prorease activity in in Vitro and in Vivo experiments. Jpn J Pharmacol. 1984;35:203–27.

Article  CAS  PubMed  Google Scholar 

Kinney TB, Valji K, Rose SC, Yeung DD, Oglevie SB, Roberts AC, Ward DM. Pulmonary embolism from pulse-spray pharmacomechanical thrombolysis of clotted hemodialysis grafts: urokinase versus heparinized saline. J Vasc Interrv Radiol. 2000;11:1143–52.

Article  CAS  Google Scholar 

Forsberg U, Jonsson P, Stegmayr C, Stegmayr B. A high blood level in the air trap reduces microemboli during hemodialysis. Artif Organs. 2012;35:525–9.

Article  Google Scholar 

Hoffmann M, Hofmann-Winkler H, Smith JC, Krüger N, Arora P, Søresen LK, Søgaard OS, Hasselstøm JB, Winkler M, Hempel T, Raich L, Olsson S, Danov O, Jonigk D, Yamazoe T, Yamatsuta K, Mizuno H, Ludwig S, Noé F, Kjolby M, Braun A, Sheltzer JM, Pöhlmann S. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. EbioMedicin. 2021;65: 103255.

Article  CAS  Google Scholar 

Atkins P. Physical chemistry. Oxford: Oxford Univ. Press; 2014. p. 11–3.

Google Scholar